We can’t show the full text here under this license.
Abstract
Resmetirom is a recently FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH).
- Resmetirom is associated with the reduction of intra-hepatic lipids and improvement in liver tissue health.
- Key outcomes show that resmetirom may lead to resolution of non-alcoholic steatohepatitis (NASH) and improvement in fibrosis in a significant percentage of patients.
- Common gastrointestinal side effects are noted, but the drug maintains a favorable safety profile.
- Ongoing phase 3 trials aim to provide essential information on the long-term efficacy and safety of resmetirom.
Simplified